Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive ...

Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administration Phase 1/2 clinical data for VYD2311 to date are ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board, or DSMB, for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study.

-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is among the 12 Best Genomics Stocks to Invest In. TheFly reported on December 2, 2025, that Beam Therapeutics Inc. (NASDAQ:BEAM) has released revised safety and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...

Iadademstat, a selective LSD1 inhibitor, is being tested with immune checkpoint inhibitors for extensive-stage SCLC in a phase 1/2 trial. The trial, led by the National Cancer Institute, evaluates ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 metabolic dysfunction-associated steatohepatitis (MASH) study, while still ...